A nine-year study conducted on 269 post-operative liver-cancer patients using AHCC[R] (Active Hexose Correlated Compound) was recently published in the Journal of Hepatology (2002;37:78-86), The Official Journal of the European Association for the Study of Liver. The study demonstrated a significant and positive influence on immune function, concluding that AHCC can improve the prognosis for postoperative hepatocellular carcinoma (HCC) patients.
In vitro experiments have shown that AHCC enhances natural killer cell activity, and may be considered a potent biological response modifier in the treatment of cancer patients. A prospective cohort study was performed from February 1, 1992 to December 31, 2001. A total of 269 consecutive patients with histologically confirmed HCC were studied. The study examined ten different parameters related to liver function after surgery.
Of the 269 patients, 113 received AHCC orally after undergoing curative surgery. Researchers at the University of Osaka, Japan, concluded that, compared with the control group, the AHCC group had a significantly longer period with no disease recurrence, a higher survival rate, and an increased overall survival rate.
AHCC is derived from a highly specialized manufacturing process developed in the mid-1980s that relies on the hybridization of several species of mushrooms cultivated in Japan. According to industry analysts in Japan, over 700 hospitals and medical clinics recommend AHCC to patients in that country as part of an immune enhancement maintenance regimen, creating a $150 million (USD) industry.
AHCC has been the subject of numerous clinical studies conducted at prestigious Japanese institutions such as Hokkaido University, Kyomin University and Teikyo University. Currently 40,000 individuals worldwide use the nutritional supplement monthly.
The abstract of the study can be viewed at http://www.elsevier.com.
Integrated Marketing Group
P.O. Box 311
Rye, New York 10580 USA
COPYRIGHT 2002 The Townsend Letter Group
COPYRIGHT 2003 Gale Group